- DiPiro JT, ed. Pharmacotherapy: A Pathophysiologic Approach, 4th ed. Stamford, Conn: Appleton & Lange, 1999: 29–30.
- Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician 1998;57: 107–116.
- Goodman LS, Limbird LE, Milnoff PB, Gilman AG, Hardman JG, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1996: 12–16.
- Belpaire FM, Bogaert MG. Cytochrome P450: genetic polymorphism and drug interactions. Acta Clinica Belgica 1996;51: 254–260.
- Nelson WE, ed. Textbook of Pediatrics, 15th ed. Philadelphia: WB Saunders Co, 1996: 1127.
- Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63: 332–341.
- Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49–53.
- Abramowicz A, ed. The Medical Letter July 1999;41: 61–62.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 13, 2000 - Issue 4